Shares of CeriBell (NASDAQ:CBLL – Get Free Report) reached a new 52-week low on Monday . The company traded as low as $20.06 and last traded at $20.13, with a volume of 13957 shares trading hands. The stock had previously closed at $20.93.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on CBLL shares. William Blair started coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. Bank of America started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target for the company. TD Cowen lifted their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Canaccord Genuity Group started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.60.
Check Out Our Latest Report on CBLL
CeriBell Stock Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.06 million. As a group, equities research analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- Expert Stock Trading Psychology Tips
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What does consumer price index measure?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Are Some of the Best Large-Cap Stocks to Buy?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
